Cochrane group rejects Roche’s offer of “advisory board” to discuss analysis of oseltamivir dataBMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e8072 (Published 26 November 2012) Cite this as: BMJ 2012;345:e8072
- Zosia Kmietowicz
Cochrane Collaboration researchers have repeated their plea to the drug giant Roche for the company to honour its promise made in 2009 to make public its full clinical study reports on oseltamivir (Tamiflu).
They were responding to an offer by Roche to set up a multiparty advisory board to review what type of analysis of data on oseltamivir would be useful to researchers who are trying to establish the drug’s effectiveness.
Although they read the offer “with great interest,” the researchers added, “On 8 December 2009, you promised in the BMJ to make ‘full study reports’ available ‘within the coming days to physicians and scientists undertaking legitimate analyses.’ . . . We have requested these data numerous times and have yet to receive a single full study report from Roche. We are still waiting for Roche to honor its promise.”
The Cochrane group said that the data were essential …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial